SK2220127072

Patient Name : ARUNA BAJAJ Lab No.
: SK2220127072
Age / Sex : 76 Y / F Registration On : 21-01-2022
Referred By : SELF Collection Date : 21/Jan/2022 03:53PM
Patient ID : UYSF.0000031023 Received Date : 21/Jan/2022 07:09PM
Centre : BTC SAKET Approved Date : 21/Jan/2022 09:43PM
ILI EXTENDED PANEL

Test Name Result Biological Ref. Interval Method
Kidney Function Test , Serum

Blood Urea 25 mg/dL 15-36 Urease, Colorimetric
Blood Urea Nitrogen 11.68 mg/dL 7 - 17 Calculated
Creatinine 0.8 mg/dL 0.5-1.04 Enzymatic
Uric Acid 7.0 mg/dL 2.5 - 6.2 Uricase , Colorimetric
Calcium 8.9 mg/dL 8.4 - 10.2 Arsenazo III
Phosphorus 3.9 mg/dL 2.5 - 4.5 Phosphomolybdate reduction
Sodium 136 mmol/L 137-145 ISE Direct
Potassium 5.5 mmol/L 3.5 - 5.1 ISE Direct
Chloride 102 mmol/L 98 - 107 ISE Direct
BUN/Creatinine Ratio 14.60 Ratio Calculated
Urea/Creatinine Ratio 31 Ratio Calculated
-----------------------------------------------------------------------------------------------------------------
The laboratory is NABL Accredited for tests in KFT
-----------------------------------------------------------------------------------------------------------------
Technology: Dry Chemistry (VITROS MicroSlide, MicroSensor and Intellicheck Technology)
-----------------------------------------------------------------------------------------------------------------
Sample Type: Serum
Analyzer: Fully Automated Biochemistry and ImmunoAssay Analyzer: VITROS 5600
-----------------------------------------------------------------------------------------------------------------
Remarks: Please correlate results clinically.
-----------------------------------------------------------------------------------------------------------------
Ferritin , Serum 126 ng/mL 11.1-264 ECLIA
Biological Reference Range for Ferritin

Category Total Observed Range
Iron Deficiency 0.68 - 34.5
Other Anemia 13.0 - 1390.8
Iron Overload 334.6 - 8573.0
Renal Dialysis 31.3 - 1321.2
Chronic Liver Disease 7.9 - 12826.0
---------------------------------------------------------------------------------
Sample Type: Serum
Technology: VITROS MicroWell, MicroSensor and Intellicheck Technology
Analyzer: Fully Automated Integrated Biochemistry and ImmunoAssay Analyzer: VITROS 5600
---------------------------------------------------------------------------------
Clinical Significance: Ferritin is found in serum in low concentrations and is directly proportional to the body~s iron stores. Serum ferritin concentration, when analyzed with other factors such as serum iron, iron-binding capacity, and
tissue iron stores, is valuable in the diagnosis of iron -deficiency anemia, anemia of chronic infection, and conditions such as thalassemia and hemochromatosis that are associated with iron overload. Measurement of serum ferritin is
particularly valuable in distinguishing iron-deficiency anemia caused by low iron stores from those resulting from inadequate iron utilization.
---------------------------------------------------------------------------------
Remarks: Please correlate results with clinical conditions
---------------------------------------------------------------------------------
Scan to Validate Report Page 1 of 11
HOD Healthcare Pvt. Ltd., 266, Hauz Rani Market, Opposite Max Hospital-Saket, Delhi-110017
Patient Name : ARUNA BAJAJ Lab No. : SK2220127072
ILI EXTENDED PANEL

*** End Of Report ***
SIN No:CL00555957
ILI EXTENDED PANEL

C-Reactive Protein , Serum

CRP [Quantitative] 5.8 mg/L <5.0 Immunoturbidimetric
-------------------------------------------------------------------------------------------------------------------
Clinical Significance of CRP:
C-reactive protein (CRP) is a serum protein, which issynthesized in the liver. Its rate of synthesis and secretion increases within hours of an acute injury or the onset of inflammation and may reach as high as 20 times the normal levels.
Elevated serum concentration of CRP indicates active tissue damage process and CRP measurement thus provides a simple screening test for organic disorders. Clinical Significance of CRP stands important for
- Inflammatory disorders
- Management of neonatal septicaemia and meningitis
- Postoperative surveillance
- Myocardial infarction
- CRP is found to be present after the first trimester of pregnancy and persists until delivery.
- CRP levels increase in women who are on oral contraceptives.
- CRP response is not affected by the commonly used anti-inflammatory or immunosuppressive drugs, including steroids, unless the disease activity is affected.
Advise for CRP:
Since CRP production is a non-specific response to tissue injury, it is recommended that results of the test should be correlated with clinical findings to arrive at the final diagnosis. In cases where an increase in CRP levels is suspected,
but the screening tests shows negative results, semiquantitation should be done to rule out prozone effect.
---------------------------------------------------------------------------------
Sample Type: Serum
Technology: VITROS MicroTip, MicroSensor & Intellicheck
Analyzer: Fully Automated Biochemistry and Immunology Analyzer : VITROS 5600
---------------------------------------------------------------------------------
Advise: Please correlate results with clinical conditions
---------------------------------------------------------------------------------
SIN No:CL00555957
ILI EXTENDED PANEL

Lactate Dehydrogenase , Serum 206 U/L 120 - 246 Pyruvate to Lactate Kinetic
method
---------------------------------------------------------------------------------
Sample Type: Serum
Technology: Dry Chemistry (VITROS MicroSlide, MicroSensor & IntelliCheck Technology)
Analyzer: Fully Automated VITROS 5600 Analyzer
---------------------------------------------------------------------------------
Clinical Significance:
* Lactate dehydrogenase (LDH) activity is present in all cells of the body with highest concentrations in heart, liver, muscle, kidney, lung, anderythrocytes. Serum LDH is elevated in a number of clinical conditions like megaloblastic
anemia, untreated pernicious anemia, Hodgkin's disease, abdominal and lung cancers, severe shock, and hypoxia.
* Moderate to slight increases in LDH levels are seen in myocardial infarction (MI), pulmonary infarction, pulmonary embolism, leukemia, hemolytic anemia, infectious mononucleosis, progressive muscular dystrophy (especially in the
early and middle stages of the disease), liver disease, and renal disease.
* In liver disease, elevations of LDH are not as great as the increases in aspartate amino transferase (AST) and alanine aminotransferase (ALT).
* Increased levels of the enzyme are found in about one third of patients with renal disease, especially those with tubular necrosis or pyelonephritis. However, these elevations do not correlate well with proteinuria or other parameters of
renal disease. On occasion a raised LDH level may be the only evidence to suggest the presence of a hidden pulmonary embolus.
---------------------------------------------------------------------------------
Cautions:
* Red blood cells contain much more lactate dehydrogenase (LDH) than serum. A hemolyzed specimen is not acceptable. LDH activity is 1 of the most sensitive indicators of in vitro hemolysis. Causes can include transportation via
pneumatic tube, vigorous mixing, or traumatic venipuncture.
* While increases in serum LDH also are seen following a myocardial infarction, the test has been replaced by the determination of troponin.
---------------------------------------------------------------------------------
Remarks: Please correlate results with clinical conditions.
---------------------------------------------------------------------------------
SIN No:CL00555957
Procalcitonin , Serum
Procalcitonin 0.059 ng/mL <0.077 CLIA
---------------------------------------------------------
Biological Reference Range for Procalcitonin
• Diagnosis of Sepsis
PCT levels (ng/mL) Interpretation
< 0.077 Healthy individual
< 0.5 Systemic infection (sepsis) is unlikely.
0.5-2.0 Systemic infection (sepsis) is possible.
2.0-10.0 Systemic infection (sepsis) is likely, unless other causes are known.
>10.0 Important systemic inflammatory response, almost exclusively due to severe bacterial sepsis or septic shock.
• Decision Making on Antibiotic Therapy
PCT levels (ng/mL) Interpretation
< 0.10 Use of antibiotics is strongly discouraged
0.10-0.25 Antibiotic therapy discouraged
0.25-0.50 Antibiotic therapy recommended.
>0.50 Antibiotic therapy strongly recommended
---------------------------------------------------------
Clinical Sgnificance: Procalcitonin, the prohormone of calcitonin is below limit of detection (0.05 ng/ml) in healthy individuals. It rises in response to an inflammatory stimulus especially of bacterial origin. It does not rise significantly with
viral or non infectious inflammations.
---------------------------------------------------------
Clinical Notes: PCT levels can be elevated in non infectious causes like:
*The first days after a major trauma, major surgical intervention, burns, treatment with OKT3 antibodies and other drugs stimulating the release of pro-inflammatory cytokines, small cell lung cancer, medullary C-cell carcinoma of thyroid.
*Patients with prolonged or severe cardiogenic shock, prolonged severe organ perfusion anomalies.
* Neonates < 48 hrs of life.
*Patients with PCT values <2 ng/ml should be closely monitored both clinically and by reassessing PCT within 6-24 hrs.
---------------------------------------------------------
Please correlate results clinically.
---------------------------------------------------------
SIN No:CL00555957
ILI EXTENDED PANEL

D-Dimer , Sodium Citrate 3.2%

D-Dimer 0.65 µg/mL FEU <0.50 Latex Enhanced Immunoassay
------------------------------------------------------------------------
Clinical Significance of D-Dimer: The formation of D-Dimer requires three hemostatic stages: formation of clot (coagulation), Factor XIIIa crosslinking, and clot breakdown of fibrin (fibrinolysis). Several studies have shown a
correlation of increased D-dimer levels with clinical conditions that relate to the formation of fibrin, mirroring an in vivo lysis of formed cross-linked fibrin. These conditions include deep venous thrombosis (DVT), disseminated
intravascular coagulation (DIC), pulmonary embolism (PE), postoperative states, malignancy, trauma, and pre-eclampsia. Signs and symptoms of DVT are non-specific and present in a myriad of non-thrombotic disorders; hence, timely,
accurate, and fast D-dimer assay could provide significant utility for managing and monitoring patients with suspected DVT. Pulmonary embolism may result from deep vein thrombosis; hence, stressing an essential need of early
diagnosis and treatment of DVT.
------------------------------------------------------------------------
Clinical Notes for D-Dimer:
1. D dimer half-life is approximately 6 hours in circulation of individuals with normal renal function. Patients with stabilized clots and not undergoing active fibrin deposition and plasmin activation may not give detectable D dimer elevations,
anti-coagulant therapy.
2. In PE, the larger the clot size, higher the expected level of circulating D dimer. Conversely, the amount of D-dimer release from very small clots may be diluted by the circulation and may not give a detectable increase.
3. Fibrinolysis is a highly regulated process and in delicate dynamic balance. In case of hereditary, acquired deficiency and dysfunction of Fibrinogen, the rate of fibrinolysis will be altered there by not givin detectable D dimer level
4. False positive may be seen with high levels of rheumatoid factor,bilirubin, lipemic sera and hemolysed blood.
----------------------------------------------------------------------------------------
Advise: The D-Dimer test should be read in conjunction with other clinical parameters.
----------------------------------------------------------------------------------------
SIN No:CO00045298
ILI EXTENDED PANEL

CBC , EDTA Whole Blood

Hemoglobin 12.0 gm/dL 12.0 - 15.0 Photometric Measurement
Total RBC 4.41 million/µL 3.8 - 4.8 Coulter Principle
Platelet Count 180 X 10³ / µL 150 - 410 x 10³/µL Coulter Principle
Total Leucocyte Count (WBC) 6.0 X 10³ / µL 4.0 - 10.0 Coulter Principle
Differential Leucocyte Count (DLC)
Neutrophils 62 % 40 - 80 VCSn/Microscopy
Lymphocytes 29 % 20 - 40 VCSn/Microscopy
Monocytes 08 % 2 - 10 VCSn/Microscopy
Eosinophils 01 % 1-6 VCSn/Microscopy
Basophils 00 % 0-1 VCSn/Microscopy
Absolute Neutrophil Count 3.72 X 10³ / µL 2.0 - 7.5 VCSn/Microscopy
Absolute Lymphocyte Count 1.74 X 10³ / µL 1.0 - 4.0 VCSn/Microscopy
Absolute Monocyte Count 0.48 X 10³ / µL 0.2 - 1.0 VCSn/Microscopy
Absolute Eosinophil Count 0.06 X 10³ / µL 0.04 - 0.44 VCSn/Microscopy
Absolute Basophil Count 0.01 X 10³ / µL 0.00 - 0.30 VCSn/Microscopy
Indices
Hematocrit 36.1 % 36 - 46 Calculated
Mean Corpuscular Volume (MCV) 81.8 fL 83 - 101 Calculated
Mean Corp. Hemoglobin (MCH) 27.2 pg 27 - 32 Calculated
MCH Concentration (MCHC) 33.2 g/dl 31.5 - 34.5 Calculated
Red Cell Dist. Width (RDW-CV) 14.1 % 11.5 - 14.5 Calculated
Red Cell Dist. Width (RDW-SD) 41.6 fL 39 - 46 Calculated
Mean Platelet Volume (MPV) 11.4 fL 7-5 - 12.0 Calculated
Neutrophil-Lymphocyte Ratio (NLR) 2.14 Calculated
-----------------------------------------------------------------------------------------------------------------
Remarks: Please correlate with clinical conditions.
-----------------------------------------------------------------------------------------------------------------
SIN No:ED00297707
ESR , EDTA Whole Blood 56 mm/hr <20 Modified Westergren
--------------------------------------------------------------
Laboratory is NABL Accredited for ESR (Erythrocyte Sedimentation Rate).
--------------------------------------------------------------
Clinical Notes for ESR:
Increased ESR is seen in:
- In any chronic infection
- Active rheumatic fever
- Acute myocardial infection
- Nephrosis
- All type of shocks
Decreased ESR is seen in:
- Newborn infants
- Polycythemia
- Congestive heart failure
- Sickel cell anaemia
--------------------------------------------------------------
--------------------------------------------------------------
Hb A1c , EDTA Whole Blood

HbA1C 6.7 % 4.8-5.7 HPLC
90 Day Average Blood Glucose 146 mg/dl 90 - 120 Calculated
Biological Reference Range (ADA 2019 Guidelines):

Normal (Non-diabetic): <5.7%
Prediabetics (Predisposed to developing diabetes): 5.7 to 6.4%
Diabetic : >6.5%
Therapeutic goals for glycemic control (ADA 2019 Guidelines)
Adults:-
- Goal of therapy < 7.0 % HbA1C
- Action Suggested > 8.0 % HbA1C
Pediatric Patients:
- Toddlers and Pre-school: < 8.5 % (But >7.5%)
- School Age (6-12 yrs): < 8 %
- Adolescents and young adults (13-19 years): <7.5%
------------------------------------------------------------------------------------------
Summary & Explanation of the Test: The concentration of HbA1c within red blood cells reflects the average level of blood sugar over the previous 3 months. The level of HbA1c, therefore, rises proportionately in patients with higher
levels of blood sugar, such as those with uncontrolled or undiagnosed diabetes. The 90-Day Average Blood Sugar value is derived from HbA1c, this value estimates the average blood sugar level over the past 90 days.
Some of the factors that influence HbA1c and its measurement [Adapted from Gallagher et al (24)]
1. Erythropoiesis
Increased HbA1c: iron, vitamin B12 deficiency, decreased erythropoiesis.
Decreased HbA1c: administration of erythropoietin, iron, vitamin B12, reticulocytosis, chronic liver disease.
2. Altered Haemoglobin
Genetic or chemical alterations in hemoglobin: hemoglobinopathies, HbF, methemoglobin, may increase or decrease HbA1c.
3. Glycation
Increased HbA1c: alcoholism, chronic renal failure, decreased intraerythrocytic pH.
Decreased HbA1c: aspirin, vitamin C and E, certain hemoglobinopathies, increased intra-erythrocyte pH.
Variable HbA1c: genetic determinants.
4. Erythrocyte destruction
Increased HbA1c: increased erythrocyte life span: Splenectomy.
Decreased A1c: decreased erythrocyte life span: hemoglobinopathies, splenomegaly, rheumatoid arthritis or drugs such as antiretrovirals, ribavirin, and dapsone.
5. Assays
Increased HbA1c: hyperbilirubinemia, carbamylated hemoglobin, alcoholism, large doses of aspirin, chronic opiate use.
Variable HbA1c: hemoglobinopathies.
Decreased HbA1c: hypertriglyceridemia.
Increased HbA1c can also occur in iron & vitamin B12 deficiency, decreased erythropoiesis, alcoholism, chronic renal failure, decreased intraerythrocytic Ph, splenectomy, hyperbilirubinemia, carbamylated hemoglobin, alcoholism, large
doses of aspirin, chronic opiate use.
Decreased HbA1c can occur in the administration of erythropoietin, iron, vitamin B12, reticulocytosis, chronic liver disease, aspirin, vitamin C and E, certain hemoglobinopathies, increased intra-erythrocyte pH, hemoglobinopathies,
splenomegaly, rheumatoid arthritis or drugs such as antiretrovirals, ribavirin, and dapsone, hypertriglyceridemia.
------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------
SIN No:ED00297707
ILI EXTENDED PANEL

Interleukin-6 , EDTA Whole Blood

Interleukin-6 11.90 pg/mL <4.4 CLIA
----------------------------------------------------
Clinical Significance: Elevated IL-6 serum or plasma levels may occur in a variety of acute and chronic diseases associated with inflammation, such as sepsis, neoplastic disorders, autoimmune diseases, alcoholic liver disease, and
infections, or transplant rejection.
----------------------------------------------------
Biological Reference Interval: Biological Reference Interval is suggested at <4.4 pg/mL according to the SIEMENS Centaur IFU Manual.
----------------------------------------------------
Advise: Please correlate results clinically.
----------------------------------------------------

In case of any discrepancy due to typing error, kindly get it rectified immediately.This is professional opinion, not a diagnosis.
ILI EXTENDED PANEL

Result(s) Pending :
- Liver Function Test
SIN No:SE00062380
Experience Care
Conditions Of Reporting
The report results are for information and interpretation for your referring doctor. Reports are to be
correlated with the patient’s clinical history.
Biological Reference Range/Interval is suggested for your Gender and Age on the basis of available
literature. All reference ranges are to be reconsidered by physician’s advice for your specific care.
This Medical Report is a professional opinion, not a diagnosis.
The report will carry the name and age provided at the time of registration. To maintain confidentiality,
certain reports may not be e-mailed at the discretion of the management.
All the notes and interpretation beneath the pathology result in the report provided are for educational
purpose only. It is not intended to be a substitute for physician's consultation.
Results of tests may vary from laboratory to laboratory and in some parameters from time to time for the
same patients. Test results and reference range may also vary depending on the technology and
methodology used. Laboratory test results may also vary depending on the age, sex, time of the day
sample has been taken, diet, medication and limitation of modern technology.
In case of any unexpected or alarming test results, please contact us immediately for re-confirmation,
further discussion, clarifications and rectifications, if needed.
In case of any discrepancy due to typing error, kindly get it rectified immediately.
Neither HOD or its employees/representatives assume any liability or responsibility for any loss or
damage that may be incurred by any person as a result of interpreting the meaning of this report.
Test results are not valid for medico legal purposes.
In case of any issues or suggestions about your test results, please email us on
quality@houseofdiagnostics.com
The courts (forums) at Delhi shall have exclusive jurisdiction in all disputes/claims concerning the tests
and the results of the tests. Our liability is limited to the amount of investigations booked with us.
DOC#COR20200707
Facilities Available
Radiology Pathology Nuclear Medicine
3T MRI & 1.5T MRI Biochemistry India’s First Simultaneous PET-MRI
CT Scan Immunoassay Whole Body PET/CT Scan
Digital X-Ray Hematology DTPA / DMSA Renal Scans
Mammography Clinical Pathology Thyroid Scan
Open / Standing MRI Serology Whole Body Bone Scan
Bone DEXA Scan Microbiology HIDA Scan • Rest MUGA
Cardiology Investigations Neurology Investigations Dental Imaging

ECG (Electrocardiogram) EEG - ElectroEncephaloGram CBCT - Cone Beam CT Scan
Echocardiography EMG - ElectroMyoGraphy OPG - OrthoPantomoGram
TMT NCV - Nerve Conduction Velocity
Stress Echocardiography VEP - Visual Evoked Response Other Tests
Stress Thallium SSEP PFT

SK2220127072

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

SK2220127072

Uploaded by

Copyright:

Available Formats

Patient Name : ARUNA BAJAJ Lab No.

ILI EXTENDED PANEL

Kidney Function Test , Serum

Ferritin , Serum 126 ng/mL 11.1-264 ECLIA

Biological Reference Range for Ferritin

Scan to Validate Report Page 1 of 11

ILI EXTENDED PANEL

*** End Of Report ***

Scan to Validate Report Page 2 of 11

ILI EXTENDED PANEL

C-Reactive Protein , Serum

*** End Of Report ***

Scan to Validate Report Page 3 of 11

ILI EXTENDED PANEL

*** End Of Report ***

Scan to Validate Report Page 4 of 11

Test Name Result Biological Ref. Interval Method

PCT levels (ng/mL) Interpretation

< 0.077 Healthy individual

< 0.5 Systemic infection (sepsis) is unlikely.

0.5-2.0 Systemic infection (sepsis) is possible.

PCT levels (ng/mL) Interpretation

< 0.10 Use of antibiotics is strongly discouraged

0.10-0.25 Antibiotic therapy discouraged

0.25-0.50 Antibiotic therapy recommended.

>0.50 Antibiotic therapy strongly recommended

*** End Of Report ***

Scan to Validate Report Page 5 of 11

ILI EXTENDED PANEL

D-Dimer , Sodium Citrate 3.2%

*** End Of Report ***

Scan to Validate Report Page 6 of 11

ILI EXTENDED PANEL

CBC , EDTA Whole Blood

*** End Of Report ***

Scan to Validate Report Page 7 of 11

Test Name Result Biological Ref. Interval Method

ESR , EDTA Whole Blood 56 mm/hr <20 Modified Westergren

Hb A1c , EDTA Whole Blood

Biological Reference Range (ADA 2019 Guidelines):

Scan to Validate Report Page 8 of 11

Test Name Result Biological Ref. Interval Method

*** End Of Report ***

Scan to Validate Report Page 9 of 11

ILI EXTENDED PANEL

Interleukin-6 , EDTA Whole Blood

*** End Of Report ***

Scan to Validate Report Page 10 of 11

ILI EXTENDED PANEL

Scan to Validate Report Page 11 of 11

This Medical Report is a professional opinion, not a diagnosis.

Test results are not valid for medico legal purposes.

Cardiology Investigations Neurology Investigations Dental Imaging

You might also like

* End Of Report *

* End Of Report *

* End Of Report *

* End Of Report *

* End Of Report *

* End Of Report *

* End Of Report *

* End Of Report *